ATE382048T1 - Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen - Google Patents

Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen

Info

Publication number
ATE382048T1
ATE382048T1 AT03752559T AT03752559T ATE382048T1 AT E382048 T1 ATE382048 T1 AT E382048T1 AT 03752559 T AT03752559 T AT 03752559T AT 03752559 T AT03752559 T AT 03752559T AT E382048 T1 ATE382048 T1 AT E382048T1
Authority
AT
Austria
Prior art keywords
pyrazolopyrimdines
inhibitors
cyclin dependent
dependent kinases
kinases
Prior art date
Application number
AT03752559T
Other languages
English (en)
Inventor
Michael Dwyer
Timothy Guzi
Kamil Paruch
Ronald Doll
Kartik Keertikar
Viyyoor Girijavallabhan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE382048T1 publication Critical patent/ATE382048T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03752559T 2002-09-19 2003-09-17 Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen ATE382048T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41213802P 2002-09-19 2002-09-19

Publications (1)

Publication Number Publication Date
ATE382048T1 true ATE382048T1 (de) 2008-01-15

Family

ID=32030811

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03752559T ATE382048T1 (de) 2002-09-19 2003-09-17 Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen

Country Status (18)

Country Link
US (1) US7151104B2 (de)
EP (1) EP1539750B1 (de)
JP (1) JP4845380B2 (de)
KR (1) KR20050072090A (de)
CN (1) CN100475812C (de)
AR (1) AR041292A1 (de)
AT (1) ATE382048T1 (de)
AU (1) AU2003270846B2 (de)
CA (1) CA2499593C (de)
DE (1) DE60318321T2 (de)
ES (1) ES2297203T3 (de)
IL (1) IL167432A (de)
MX (1) MXPA05003059A (de)
MY (1) MY136840A (de)
NZ (1) NZ538595A (de)
TW (1) TWI283243B (de)
WO (1) WO2004026872A1 (de)
ZA (1) ZA200502271B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
PT1506203E (pt) 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ES2403558T3 (es) * 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
US20090047278A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Combinational Use of Sulfonamide Compound
US20090047365A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
US7304074B2 (en) * 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
BRPI0607907A2 (pt) * 2005-04-07 2016-11-08 Teijin Pharma Ltd derivado de pirazolo [1,5-a] piridina ou sal do mesmo, composição farmacêutica, inibidor de mapkap-k2, e, agente de tratamento ou prevenção
US7417053B2 (en) 2005-04-07 2008-08-26 Teijin Pharma Limited Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
EP1931641B1 (de) 2005-09-09 2010-08-25 Schering Corporation Neue 4-cyano-, 4-amino-, und 4-aminomethylderivative von pyrazolo[1,5-a]pyridinen, pyrazolo[1,5-c]pyrimidinen und 2h-indazolverbindungen und 5-cyano-, 5-amino- und 5-aminomethylderivative von imidazo[1,2-a]pyridinen, und imidazo[1,5-a]pyrazinverbindungen als inhibitoren der cyclinabhänggen kinase
EP2096923B1 (de) * 2006-11-27 2014-01-22 H. Lundbeck A/S Heteroarylamidderivate
KR20090031122A (ko) * 2007-09-21 2009-03-25 주식회사 중외제약 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
AU2016243529B2 (en) * 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3377908B1 (de) 2015-11-18 2020-08-05 Genzyme Corporation Biomarker von polyzystischer nierenkrankheit und verwendungen davon
US10968215B2 (en) * 2016-09-07 2021-04-06 Shanghai Haihe Pharmaceutical Co., Ltd. Pyrido five-element aromatic ring compound, preparation method therefor and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69627195T2 (de) * 1995-11-01 2004-01-29 Novartis Ag Purinderivate und verfahren zu ihrer herstellung
ZA9811178B (en) 1997-12-13 2000-06-07 Bristol Myers Squibb Co Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors.
SE9802794D0 (sv) * 1998-08-21 1998-08-21 Astra Ab New compounds
FR2801308B1 (fr) * 1999-11-19 2003-05-09 Oreal COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES
WO2001056607A1 (en) * 2000-02-03 2001-08-09 Eisai Co., Ltd. Integrin expression inhibitors
WO2002050079A1 (fr) * 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
EE05234B1 (et) * 2001-03-08 2009-12-15 Astrazeneca Ab 6-karboksamidoimidaso[1,2-a] pridiinihendite kasutamine ravimi p?hjustatud maohaavandi v„ltimiseks
CN1202896C (zh) * 2002-02-07 2005-05-25 北京燕化高新技术股份有限公司 空气分离时纯化空气的方法

Also Published As

Publication number Publication date
TW200409775A (en) 2004-06-16
AU2003270846B2 (en) 2006-11-23
TWI283243B (en) 2007-07-01
NZ538595A (en) 2006-04-28
HK1071758A1 (en) 2005-07-29
ES2297203T3 (es) 2008-05-01
DE60318321T2 (de) 2008-12-11
MXPA05003059A (es) 2005-05-27
AR041292A1 (es) 2005-05-11
US20040097516A1 (en) 2004-05-20
JP4845380B2 (ja) 2011-12-28
ZA200502271B (en) 2005-09-19
MY136840A (en) 2008-11-28
WO2004026872A1 (en) 2004-04-01
CA2499593C (en) 2011-08-16
CN100475812C (zh) 2009-04-08
EP1539750A1 (de) 2005-06-15
CA2499593A1 (en) 2004-04-01
US7151104B2 (en) 2006-12-19
IL167432A (en) 2010-05-17
KR20050072090A (ko) 2005-07-08
DE60318321D1 (en) 2008-02-07
CN1681816A (zh) 2005-10-12
EP1539750B1 (de) 2007-12-26
AU2003270846A1 (en) 2004-04-08
JP2006503060A (ja) 2006-01-26

Similar Documents

Publication Publication Date Title
NO20045220L (no) Heterocykliske inhibitorer for kinaser
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
NO20050636L (no) Inhibitorer av tyrosinkinaser
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
ATE378336T1 (de) Imidazopyridine als hemmstoffe cyclin abhängiger kinasen
ATE369356T1 (de) Pyridazinon-derivate als cdk2-hemmer
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
ATE378337T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE374201T1 (de) 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
SI1562589T1 (sl) Diaminotriazoli, koristni kot inhibitorji proteinkinaz
ATE455546T1 (de) Aminotriazol-verbindungen als proteinkinase- hemmer
SI1534290T1 (sl) Novi inhibitorji kinaz
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
EP1660436A4 (de) Cathepsininhibitoren
EP1534268A4 (de) Tyrosin-kinase-hemmer
DE60324208D1 (de) Biarylsulfonamide als mmp-inhibitoren
DK1811998T3 (da) Triazoler anvendelige som inhibitorer af proteinkinaser
EP1697331A4 (de) Inhibitoren von mitotischem kinesin
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
EP1651599A4 (de) Tyrosin-kinase-hemmer
EP1496897A4 (de) Tyrosinkinase-hemmer
EP1570847A4 (de) Phosphodiesterase 10a-hemmer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties